# US 12,478,629 B2 · Use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,478,629 B2
- Document ID: US12478629B2
- Status: Granted
- Kind: B2
- Application number: 18/475,736
- Filed: 2023-09-27
- Published: 2024-01-18
- Granted: 2025-11-25
- Earliest claimed: 2018-07-30
- Assignees: Virbac
- Applicants: Virbac
- Inventors: Bertrand Havrileck; Pierre Jasmin; David Mcgahie
- Web page: https://patentgrep.com/patent/US12478629B2

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0046: {Ear}
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/16: Otologicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure is directed to glucocorticoids for the treatment of epithelial microbial infections in fluid-containing organ having a natural exterior orifice in mammals; this new therapeutic use finds particular interest in the treatment of epithelial microbial infections of ear (such as otitis extema), udder (such as mastitis), and uterus (such as endometritis).

## Claims

### Claim 1

A method for the treatment and/or the prevention of an epithelial microbial infection of the udder in a non-human mammal in need thereof, the method comprising topically administering in the udder to be treated an effective amount of hydrocortisone, a monoester, a diester or a salt thereof, wherein said epithelial microbial infection of the udder is mastitis, and
wherein said hydrocortisone, monoester, diester or salt thereof is formulated in a pharmaceutical composition also comprising a pharmaceutically acceptable carrier, and wherein said composition does not contain any antibiotic agent, antifungal agent, antiviral agent or antimicrobial agent, wherein the quantity of hydrocortisone, monoester, diester or salt thereof in the composition to be applied in the udder is comprised between 1 and 50 mg and, wherein the composition is administered: (i) at least once a day for 1 to 10 days; or (ii) at least once a week.

### Claim 2 (depends on 1)

The method of claim 1, wherein said epithelial microbial infection of the udder is caused by bacteria, fungi and/or yeasts.

### Claim 3 (depends on 2)

The method of claim 2, wherein said epithelial microbial infection of the udder is caused by bacteria.

### Claim 4 (depends on 2)

The method of claim 2, wherein the bacteria, fungi and/or yeasts are selected in the group comprising Staphylococcus spp., Escherichia coli, Klebsiella spp., Trueperella pyogenes, Streptococcus spp., Corynebacterium spp., Enterococcus spp., Pseudomonas spp., Mycoplasma spp., Prototheca spp., Candida spp., Rhodotorula, Trichosporon, Saccharomyces, Pichia, Cryptococcus, Aspergillus, Penicillum, Epicoccum, Phoma and Alternaria.

### Claim 5 (depends on 2)

The method of claim 2, wherein said epithelial microbial infection of the udder is caused by fungi and/or yeasts.

### Claim 6 (depends on 1)

The method of claim 1, wherein said non-human mammal is a non-human lactating mammal.

### Claim 7 (depends on 1)

The method of claim 1, wherein said composition is administered by topical application into the udder via the teat canal.